Over 130 participants from countries, partners and civil society came together at the Global Meeting of the Working Group on Public-Private Mix for TB prevention and care (PPM Working Group). The meeting, held on 12 November in Paris, France, was convened by the World Health Organization (WHO) and Stop TB Partnership with support from the US Agency for International Development (USAID) and the Global Fund. The meeting was organized on the sidelines of the 53rd Union World Conference on Lung Health.

For people living with HIV, tuberculosis is a big problem. It is the leading cause of death among those with HIV, who are 14 to 18 times more likely to fall ill with the disease than those without HIV, according to the World Health Organization. Latent TB infections can more easily progress to full disease due to the weakened immune system of people with HIV. Around 1 in 3 AIDS-related deaths in 2021 were also due to TB.

On World Children’s Day, that commemorates the adoption of the Convention on the Rights of the Child, WHO is announcing the launch of a new e-course on the management of tuberculosis in children and adolescents. The course will contribute towards ensuring universal access to TB prevention and care for children and adolescents.

In a recent study published in The Lancet Respiratory Medicine, researchers reported the TB-PRACTECAL clinical trial outcomes, which evaluated the efficacy and safety of oral bedaquiline, linezolid, and pretomanid (BPaL)-based regimens for pulmonary tuberculosis resistant to rifampicin.

After three years being held virtually due to the COVID-19 pandemic, the 2023 Union World Conference on Lung Health (Union Conference) took place in-person on 15-18 November 2023 in Paris, France under the theme 'Transforming evidence into practice'.

As yet another conference kicks off, it underscores the way such collaborations to end the infectious disease only serve to maintain the colonial status quo.

A combination of a new experimental compound, TBAJ-876, with pretomanid and linezolid, has the potential to become a 'universal TB regimen', shortening and improving treatment for both drug-sensitive and drug-resistant TB.

Two new clinical trials find first-ever safe and effective treatment to prevent multidrug-resistant TB in both children and adults.

endTB clinical trial offers multiple new shortened drug regimens to treat adults and children with multidrug–resistant TB.

Results of LIFT-TB operational research on BPaL regimen for treating drug-resistant TB in Central and Southeast Asia.